Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside
- PMID: 23117943
- PMCID: PMC4845954
- DOI: 10.1055/s-0032-1329194
Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy. Multiple diagnostic criteria have been established, with the primary goal of identifying neurophysiologic hallmarks of acquired demyelination. Treatment modalities have expanded to include numerous immunomodulatory therapies, although the best evidence continues to be for corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg). This review describes the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP.
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Figures
References
-
- Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 Nov;50(11):621–637. - PubMed
-
- Burns TM. Chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol. 2004 Jun;61(6):973–975. - PubMed
-
- AUSTIN JH. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone. Brain. 1958 Jun;81(2):157–192. - PubMed
-
- Katz JS, Saperstein DS, Gronseth G, Amato AA, Barohn RJ. Distal acquired demyelinating symmetric neuropathy. Neurology. 2000 Feb 8;54(3):615–620. - PubMed
-
- Lewis RA, Sumner AJ, Brown MJ, Asbury AK. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958–964. - PubMed